Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

NCT02730130 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Metastatic Triple Negative

Interventions

DRUG: Pembrolizumab
RADIATION: Radiotherapy

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]